Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition

• Published in: Proceedings of the Nutrition Society Vol. 75; no. 3; pp. 405 - 414
• Main Authors: McAuley, E., McNulty, H., Hughes, C., Strain, J. J., Ward, M.
• Format: Journal Article
• Language: English
• Published: Cambridge, UK Cambridge University Press 01.08.2016
• Subjects: adults; Animals; Biomarkers; Biomarkers - blood; Blood pressure; Blood Pressure - drug effects; Developing countries; Dietary Supplements; Disease Models, Animal; Dose-Response Relationship, Drug; Enzymes; erythrocytes; Folic Acid - administration & dosage; Folic Acid - blood; Genotype; Genotype & phenotype; glutathione-disulfide reductase; health care workers; Homozygosity; Homozygote; Human subjects; Humans; Hypertension; Ireland; Irish Section Postgraduate Meeting; Iron; LDCs; Metabolism; methylenetetrahydrofolate reductase; Methylenetetrahydrofolate Reductase (NADPH2) - genetics; Nutrition; Nutritional Requirements; Nutritional Status; patients; Polymorphism; Polymorphism, Single Nucleotide; randomized clinical trials; Randomized Controlled Trials as Topic; riboflavin; Riboflavin - blood; Riboflavin Deficiency - blood; Riboflavin Deficiency - drug therapy; risk; Risk Factors; United Kingdom; Vitamin B; United States > US; United Kingdom; Riboflavin; MTHFR C677T; Methylenetetrahydrofolate reductase; Blood pressure; Personalised nutrition; NO nitric oxide; BP blood pressure; GP general practitioners; EGRac erythrocyte glutathione reductase activation coefficient; MTHFR methylenetetrahydrofolate reductase

Clinical deficiency of the B-vitamin riboflavin (vitamin B2) is largely confined to developing countries; however accumulating evidence indicates that suboptimal riboflavin status is a widespread problem across the developed world. Few international data are available on riboflavin status as measure...